Furthermore, plasmid expression of HGF is in Phase III Clinical Trials to treat severe peripheral arterial disease in Japan [204], and adenovirus mediated HGF gene-transfer is under investigation as a potential treatment for coronary artery disease in a Phase I Clinical Trial in China [205]. This evidence concerns the gene HGF and peripheral arterial disease.